Cover Image
市場調查報告書

生殖器皰疹 : 開發中產品分析

Genital Herpes - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232819
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
生殖器皰疹 : 開發中產品分析 Genital Herpes - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 88 Pages
簡介

生殖器皰疹是代表性的性傳染病之一,任何性別皆有可能發病。這個疾病是由單純皰疹病毒(HSV)所引起,會出現食慾衰退、發熱、倦怠感、腰部·臀部·大腿部·膝部肌肉疼痛、腳根浮腫和淋巴節疼痛等症狀。

本報告提供生殖器皰疹治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

生殖器皰疹概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

生殖器皰疹:企業開發中的治療藥

生殖器皰疹:大學/機關研究中的治療藥

生殖器皰疹:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

生殖器皰疹:企業開發中的產品

生殖器皰疹:大學/機關研究中的產品

生殖器皰疹的治療藥開發企業

  • Admedus Ltd
  • Agenus, Inc.
  • AiCuris GmbH & Co. KG
  • Foamix Pharmaceuticals Ltd.
  • Genocea Biosciences, Inc.
  • GenVec, Inc.
  • Immune Design Corp.
  • JN-International Medical Corporation
  • Mymetics Corporation
  • NanoBio Corporation
  • NanoViricides, Inc.
  • PaxVax, Inc.
  • Profectus BioSciences, Inc.
  • Redbiotec AG
  • Sanofi Pasteur SA
  • Shulov Innovative Science Ltd.
  • Starpharma Holdings Limited
  • Tomegavax, Inc.
  • Vaccibody AS
  • Vaxart, Inc.
  • Vical Incorporated

生殖器皰疹:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

生殖器皰疹:暫停中的計劃

生殖器皰疹:開發中止的產品

生殖器皰疹:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10164IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2018, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Herpes - Overview
    • Genital Herpes - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Genital Herpes - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Genital Herpes - Companies Involved in Therapeutics Development
    • Abivax SA
    • Admedus Ltd
    • AiCuris GmbH & Co KG
    • Biomere LLC
    • GenVec Inc
    • Immune Design Corp
    • NanoBio Corp
    • NanoViricides Inc
    • Profectus BioSciences Inc
    • Redbiotec AG
    • Sanofi Pasteur SA
    • Starpharma Holdings Ltd
    • Vaccibody AS
    • Vical Inc
  • Genital Herpes - Drug Profiles
    • ABX-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GV-2207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus [type 1, 2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSV-529 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pritelivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Profavax HSV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Profavax HSV-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Genital Herpes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Theravax HSV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Theravax HSV-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCLHB-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCLHM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMTX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Genital Herpes - Dormant Projects
  • Genital Herpes - Discontinued Products
  • Genital Herpes - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2018: Vical Provides Update on its Genital Herpes Drug Candidate VCL-HB01
      • May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study
      • May 02, 2017: Vical Provides Update On Therapeutic Vaccine HSV-2 During its Research and Development Day
      • Apr 19, 2017: Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
      • Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
      • Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
      • Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
      • Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
      • Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
      • Feb 03, 2016: Model helps decide drug dose for clinical testing
      • Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
      • Jun 22, 2015: Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine
      • Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences
      • Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection
      • Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex Vaccine Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Genital Herpes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Genital Herpes - Pipeline by Abivax SA, H1 2018
  • Genital Herpes - Pipeline by Admedus Ltd, H1 2018
  • Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H1 2018
  • Genital Herpes - Pipeline by Biomere LLC, H1 2018
  • Genital Herpes - Pipeline by GenVec Inc, H1 2018
  • Genital Herpes - Pipeline by Immune Design Corp, H1 2018
  • Genital Herpes - Pipeline by NanoBio Corp, H1 2018
  • Genital Herpes - Pipeline by NanoViricides Inc, H1 2018
  • Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2018
  • Genital Herpes - Pipeline by Redbiotec AG, H1 2018
  • Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2018
  • Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2018
  • Genital Herpes - Pipeline by Vaccibody AS, H1 2018
  • Genital Herpes - Pipeline by Vical Inc, H1 2018
  • Genital Herpes - Dormant Projects, H1 2018
  • Genital Herpes - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Genital Herpes - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Genital Herpes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top